Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Significance: The survival benefit of antiangiogenic therapies for cancer patients has been limited, potentially due to intrinsic/acquired resistance. Deciphering and targeting resistance mechanisms are critical to improving treatment outcome, especially in cancers where antiangiogenic therapies are standard of care, such as colorectal cancer (CRC). Consistent with our clinical findings, we found up-regulation of CXCL12/CXCR4 in orthotopic CRC models and conditional Apc mutant spontaneous rectal tumors after anti-VEGFR2 treatment. CXCR4 signaling recruited immunosuppressive innate immune cells such as Ly6C low monocytes and Ly6G + neutrophils to the CRCs, conferring resistance to VEGFR2 blockade. Furthermore, we successfully targeted these pathways genetically and pharmacologically, including with an FDA-approved agent Plerixafor (AMD3100), which significantly enhanced treatment response. These strategies have the potential for rapid clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C)low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle38,39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments37–39,41”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 1×
“We specifically inhibited the infiltration of Ly6C monocytes by using Cx3cr1 mice as described previously (9, 29, 30).”
MethodNahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Self-citationCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 2×
“A endothelial growth factor (anti-VEGF) therapy is widely used in many types of solid tumors and is the current standard of care for metastatic colorectal cancer (CRC) (1).”
BackgroundSelf-citationLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 1×
“We performed flow cytometry as described previously (55).”
MethodSelf-citationYang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918 · cited 1×
“Given the important role of CXCR4 in chemotaxis of leukocytes (20, 21), we next examined the effect of AMD3100 and DC101 on the immune microenvironment.”
BackgroundCoinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“These CD11bGr1 cells were previously implicated in resistance to anti-VEGF therapy (2, 25).”
BackgroundPalucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Martin, C., Burdon, P. C. E., Bridger, G., Gutierrez-Ramos, J.-C., Williams, T. J., & Rankin, S. M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00263-2 · Cited by 770
Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal
Carlin, L. M., Stamatiades, E. G., Auffray, C., Hanna, R. N., Glover, L., Vizcay-Barrena, G., Hedrick, C. C., Cook, H. T., Diebold, S., & Geissmann, F. (2013) · Cell · doi:10.1016/j.cell.2013.03.010 · Cited by 768
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, G. A., Schols, D., Lin, S. W., Esté, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., DeClercq, E., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-072 · Cited by 760
Dancing to the tune of chemokines
Thelen, M. (2001) · Nature Immunology · doi:10.1038/84224 · Cited by 618
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy
Proia, R. L., & Hla, T. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76369 · Cited by 528
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Self-citationAn interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“These innate immune cells are also known to play a critical role in resistance to anti-VEGF therapy in some types of cancers (2, 4).”
BackgroundCXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 395
Self-citationXiao, Y., & Freeman, G. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1397 · Cited by 368
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Sitohy, B., Nagy, J. A., & Dvorak, H. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3406 · Cited by 360
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
Eash, K. J., Means, J. M., White, D. W., & Link, D. C. (2009) · Blood · doi:10.1182/blood-2008-09-177287 · Cited by 313
Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo
Tannous, B. A. (2009) · Nature Protocols · doi:10.1038/nprot.2009.28 · Cited by 303
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258 · cited 5×
“We monitored tumor growth by using a high-frequency ultrasound imaging system two times a week (Vevo 2100 system, VisualSonic) using a probe with a 40-MHz frequency (MS550S) (3).”
BackgroundMethodInfluentialSelf-citationCXCR4 Physically Associates with the T Cell Receptor to Signal in T Cells
Kumar, A., Humphreys, T. D., Kremer, K. N., Bramati, P. S., Bradfield, L., Edgar, C. E., & Hedin, K. E. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.015 · Cited by 250
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Devi, S., Wang, Y., Chew, W. K., Lima, R., A-González, N., Mattar, C. N. Z., Chong, S. Z., Schlitzer, A., Bakocevic, N., Chew, S., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130056 · Cited by 243
Cytokine-mediated regulation of CXCR4 expression in human neutrophils
Nagase, H., Miyamasu, M., Yamaguchi, M., Imanishi, M., Tsuno, N. H., Matsushima, K., Yamamoto, K., Morita, Y., & Hirai, K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.711 · Cited by 240
Endoscopic Time-Lapse Imaging of Immune Cells in Infarcted Mouse Hearts
Jung, K., Kim, P., Leuschner, F., Gorbatov, R., Kim, J. K., Ueno, T., Nahrendorf, M., & Yun, S. H. (2013) · Circulation Research · doi:10.1161/circresaha.111.300484 · Cited by 187
Self-citationLy6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Self-citationXu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
Self-citationIntertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 147
In vivo wide-area cellular imaging by side-view endomicroscopy
Kim, P., Chung, E., Yamashita, H., Hung, K. E., Mizoguchi, A., Kucherlapati, R., Fukumura, D., Jain, R. K., & Yun, S. H. (2010) · Nature Methods · doi:10.1038/nmeth.1440 · Cited by 143
Self-citationChong, S. Z., Evrard, M., Devi, S., Chen, J., Lim, J. Y., See, P., Zhang, Y., Adrover, J. M., Lee, B., Tan, L., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160800 · Cited by 142
Balabanian, K., Brotin, E., Biajoux, V., Bouchet-Delbos, L., Lainey, E., Fenneteau, O., Bonnet, D., Fiette, L., Emilie, D., & Bachelerie, F. (2012) · Blood · doi:10.1182/blood-2012-01-403378 · Cited by 141
Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
Dvorak, H. F. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000124 · Cited by 116
Chung, E., Yamashita, H., Au, P., Tannous, B. A., Fukumura, D., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008316 · Cited by 100
Self-citationHiratsuka, S., Duda, D. G., Huang, Y., Goel, S., Sugiyama, T., Nagasawa, T., Fukumura, D., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016917108 · Cited by 91
Self-citationImmune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Liu, Q., Li, Z., Gao, J., Wan, W., Ganesan, S., McDermott, D. H., & Murphy, P. M. (2015) · European Journal of Immunology · doi:10.1002/eji.201445245 · Cited by 82
Zhang, Y., Davis, C., Ryan, J., Janney, C., & Peña, M. M. O. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9591-8 · Cited by 67
Myeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 65
Morimoto‐Tomita, M., Ohashi, Y., Matsubara, A., Tsuiji, M., & Irimura, T. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-3585-0 · Cited by 44
PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer
Ghosh, M., Ai, Y., Narko, K., Wang, Z., Peters, J. M., & Hla, T. (2008) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2008.11.004 · Cited by 30
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationMacrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Metadata
- Authors
- Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., Kim, J. K., Clark, J. W., Willett, C. G., Yun, S. H., Luster, A. D., Padera, T. P., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114;
- Duke Medical Center (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-09-12
- Volume
- 114
- Issue
- 39
- Pages
- 10455-10460
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5625928
- OpenAlex
- W2754366826
- Cited by
- 138
- References
- 57
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 15 · 2023: 17 · 2022: 18 · 2021: 23 · 2020: 19 · 2019: 15 · 2018: 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (P01-CA080124, R01-CA126642, R35-CA197743, CA096915)
- HHS | National Institutes of Health (DP2 OD008780, R00 CA137167)
- DOD | U.S. Army (W81XWH-10-1-0016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- colorectal cancer, anti-angiogenic therapy, CXCR4, CXCL12, neutrophils, immunosuppression, treatment resistance, plerixafor, tumor microenvironment, innate immune cells
- MeSH terms
- Bevacizumab, Cyclams, Ramucirumab, Animals, Antibodies, Monoclonal, Antigens, Ly, Benzylamines, Heterocyclic Compounds, Mice, Inbred C57BL, Monocytes, Neutrophils, Tumor Cells, Cultured, Colorectal Neoplasms, Mice, Knockout, Receptors, CXCR4, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A, Cell Proliferation, Mice, Chemokine CXCL12, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.